Search Results - "Volf, Eva"

A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis by Volf, Eva M, Au, Shiu-Chung, Dumont, Nicole, Scheinman, Pamela, Gottlieb, Alice B

“…Evaluate the efficacy and safety of apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, in subjects with recalcitrant moderate to severe atopic…”
Get more information

Association between pediatric psoriasis and the metabolic syndrome by Au, Shiu-chung, MD, Goldminz, Ari M., BA, Loo, Daniel S., MD, Dumont, Nicole, Levine, Danielle, MD, Volf, Eva, MD, Michelon, Melissa, MD, Wang, Andrew, MD, Kim, Noori, MD, Yaniv, Shimrat, BA, Lizzul, Paul F., MD, PhD, MBA, MPH, Kerensky, Todd, MD, Lopez-Benitez, Jorge M., MD, Natter, Marc, MD, Miller, Laurie, MD, Pelajo, Christina F., MD, MSc, Davis, Trevor, MD, Gottlieb, Alice B., MD, PhD

Get full text

Prevalence of the Metabolic Syndrome in Children with Psoriatic Disease by Goldminz, Ari M., Buzney, Catherine D., Kim, Noori, Au, Shiu-Chung, Levine, Danielle E., Wang, Andrew C., Volf, Eva M., Yaniv, Shimrat S., Kerensky, Todd A., Bhandarkar, Manasa, Dumont, Nicole M., Lizzul, Paul F., Loo, Daniel S., Kulig, John W., Brown, Mary E., Lopez-Benitez, Jorge M., Miller, Laurie C., Gottlieb, Alice B.

“…Adults with psoriasis have a greater risk of developing metabolic syndrome (MetS) and cardiovascular disease (CVD), but few studies have investigated the…”
Get full text

Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts by Volf, Eva M, Levine, Danielle E, Michelon, Melissa A, Au, Shiu-Chung, Patvardhan, Eshan, Dumont, Nicole, Loo, Daniel S, Kuvin, Jeffrey, Gottlieb, Alice B

“…Adult patients with psoriasis have an increased prevalence of the metabolic syndrome (MetS) and cardiovascular disease (CVD) risk factors due to elevations of…”
Get more information

Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis by Au, Shiu-Chung, Goldminz, Ari M., Kim, Noori, Dumont, Nicole, Michelon, Melissa, Volf, Eva, Hession, Meghan, Lizzul, Paul F., Andrews, Israel D., Kerensky, Todd, Wang, Andrew, Yaniv, Shimrat, Gottlieb, Alice B.

“…Abstract Background: Palmoplantar psoriasis is a variant of psoriasis resistant to many forms of treatment. Methods: Twenty subjects with moderate-to-severe…”
Get full text

A Phase 2, Open-label, Investigator-initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects with Recalcitrant Contact or Atopic Dermatitis by Volf, Eva, Au, Shiu-Chung, Dumont, Nicole, Gottlieb, Alice

Get full text

Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients by Sorensen, Eric P, Fanucci, Kristina A, Saraiya, Ami, Volf, Eva, Au, Shiu-chung, Argobi, Yahya, Mansfield, Ryan, Gottlieb, Alice B

“…Additional studies are needed to examine the efficacy of ustekinumab in psoriasis patients who have previously been exposed to tumor necrosis factor inhibitors…”
Get more information

Pediatric Psoriasis: An Emphasis on Treatment by Volf, Eva M., Au, Shiu-Chung

“…Childhood psoriasis is a common chronic disease that may have devastating physical and psychosocial consequences. Most children are treated with topical…”
Get full text